You are here:

levetiracetam 250 500 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)

Advice

Following a resubmission

levetiracetam (Keppra) is accepted for use within NHS Scotland as adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with generalised idiopathic epilepsy.

In the pivotal study, addition of levetiracetam to existing anticonvulsant therapy achieved a significantly greater reduction in the frequency of primary generalised tonic-clonic seizures than addition of placebo.

Drug Details

Drug Name: levetiracetam 250 500 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)
SMC Drug ID: 396/07
Manufacturer: UCB Pharma Ltd
Indication: adjunctive therapy in treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with generalised idiopathic epilepsy
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Resubmission
Status: Accepted
Date Advice Published: 11 February 2008

Archived Advice

Full submission 10 September 2007

Back